En Carta Diagnostics
PrivateLast Round
Seed
Jul 10, 2026
Est. Valuation
$33M
Total Funding Raised
$7.34M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
En Carta Diagnostics operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Seed round in July 2026.
En Carta Diagnostics is a biotechnology company that develops rapid point-of-care molecular diagnostic kits with an initial focus on the early diagnosis of Lyme disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
En Carta Diagnostics Comparables
Compare En Carta Diagnostics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Anavasi Diagnostics | 79% | |
| ExGen Dx | 77% | |
| GlowDx | 73% |
For institutional investors. Book with your work email.
En Carta Diagnostics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jul 10, 2026 | ||||
| Pre Seed | May 22, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
En Carta Diagnostics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Paris Biotech Santé | Pre Seed |
| 50 Partners | Pre Seed, Seed |
| Blue Forest Ventures | Seed |
| CentraleSupélec Venture | Seed, Pre Seed |
| Ring Capital | Seed |
| Bpifrance | Seed |
| PC'up Incubator | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 19, 2026
Open roles increased to 5, representing 42% of headcount.
- Aug 22, 2026
Monthly visitors grew 33% MoM, reaching 4K.
For institutional investors. Book with your work email.
En Carta Diagnostics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about En Carta Diagnostics's valuation, stock price, and market status.
Is En Carta Diagnostics a public or private company?
En Carta Diagnostics is a private company.
What is the current stock price of En Carta Diagnostics?
En Carta Diagnostics is a private company, so its shares have no public market price. Caplight tracks En Carta Diagnostics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is En Carta Diagnostics worth (valuation)?
En Carta Diagnostics's valuation is estimated at $33.0M based on funding round data.
Can I buy En Carta Diagnostics stock?
En Carta Diagnostics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was En Carta Diagnostics's last funding round?
En Carta Diagnostics's most recent funding round was Seed on July 10, 2026.
Who are the main investors in En Carta Diagnostics?
Key investors in En Carta Diagnostics include Blue Forest Ventures, CentraleSupélec Venture.
Will En Carta Diagnostics IPO soon?
No public IPO plans have been announced for En Carta Diagnostics.
How can I track En Carta Diagnostics secondary market activity?
Caplight tracks bids, offers, and trades in En Carta Diagnostics's shares on secondary markets.